Retention bonuses should be available only after commercial success! The retention bonus now should be you get to keep your job. Our pps reflects the street opinion of management performance. We seemed to be on an upward path last year, and it then stalled. Too many disappointments. It's really OK in the long run, but shouldn't management contain themselves until the company arrives at the long-term goal? If they're that confident, they will stay put. If not confident, they will take the money and run.
Not happy about his compensation answer. For companies in the development phase, like NVIV and many others, I would consider 1/2 mil total comp value fair. When you start making money with a successful product, then talk about the bigger bucks. Until then, success in the market should be all the incentive an executive needs. Do a good job, keep your job. Mark Perrin apparently did not succeed in his last CEO job, and the company went bankrupt. That's accountability!
I have felt this way for a month. All the talk out there about Zika, including by us at the last cc. And barely any movement in pps (yes we recovered from 1.60.) BCRX management is not making an impression. All those analysts, and they are not hearing the message. Too laid back about this.
BTW, when Jon Stonehouse was at Astra Zeneca, he was responsible for clinical development and commercialization of Prilosec in the US. And now, he's giving heartburn instead of curing it!
"House Republicans, who are demanding offsetting spending cuts."
1 - cut federal funds to your red states - eg, S. Carolina gets almost $8 for every dollar paid in fed. tax
2 - cut your travel perks
3 - cut your cadillac medical plans
4 - cut your noses to spite your ugly do-nothing faces
for those who are unfamiliar with the file format, please explain the column headers -- date, symbol, ? volume, ? volume, ?volume, exchange?.
"...but at least we didn't close anywhere near the day's low. Yesterday's CC did not warrant the 9% drop at all."
On a lighter note, when a cc bombs for BCRX, the pps drops 70%, so one might say that 9% off means the cc was received well. Either way, when Mr. Stonehouse speaks, pps drops.
Rob once told me that management does occasionally look at this board. If Frankie is telling the truth, I would expect BCRX guys to be red hot, steam out of the ears angry that anybody talked about results to anyone. Of course, we all know that leaks occur all the time, spawning the oft-used phrase you hear on business news, "XXX announced a breakthrough cure for YYY after hours; ahead of the news, the stock went up 50% on the day." Haven't seen any ahead of the news action Frankie, have you?
And NBC reports first death in Puerto Rico caused by Zika virus. Oh well, "we can't pass any request that comes from that nasty ole White House!"
Astra Zeneca sold marketing rights of Ardea's gout drug to the GI drug company Ironwood. I guess there isn't a great demand for new gout treatments, and that's why Biocryst dropped 4208.
It's the realization that the Baker Brothers get things wrong too. See the cliff that Catalyst Pharmaceuticals (CPRX) fell off today. BB own 10%. Sudden fear that they may be wrong about Biocryst.
Map, see abstract 42 -
Broad-spectrum Antiviral Activity of GS-5734, a Novel Adenine Nucelotide Analog Prodrug Across the Families Filoviridae and Paramyxoviridae
"Yesterday Rob says data on 4430 will "be discussed" at the ongoing ICAR antiviral conference this week, but no data has come out publicly."
It isn't coming out publicly in a presentation at the ICAR conference this week either, although Gilead has a presentation about its antiviral. MUM's the word. This management is afraid of losing or being sued, and if you're tight-lipped you can't be accused of pumping.
conference presentation from 2012!!!! 3-1/2 years ago. That's ok, we're just taking our time, while yellow fever kills over 200 people in the past month alone.